Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by chrispion Jun 29, 2021 10:14pm
104 Views
Post# 33471207

RE:RE:RE:RE:They closed $3 million

RE:RE:RE:RE:They closed $3 million that is correct but they pay the company .41 for each share they purchase, if they should decide to purchase (they're under no obligation to do so) so the company's coffers get filled for each one they execute. Nothing nefarious about that.

Oh, and I'm not trying to hide anything over on Agoracom. If you had asked me the question here I would have answered here but not too many intelligent questions get asked on this board.
<< Previous
Bullboard Posts
Next >>